EUCTR2009-011299-32-DK进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence - D-CARE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4,509
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Disease related
- •Histologically confirmed, AJCC stage II or III breast cancer
- •See Appendix D of protocol for breast cancer grading and staging information.
- •High risk of breast cancer recurrence, defined as documented evidence of one or more of the following criteria:
- •- Biopsy evidence of breast cancer in regional lymph node(s) (LN) (node-positive disease)
- •Nodal micrometastases only are not considered node positive
- •- Tumor size > 5 cm or locally advanced disease (T4)
- •See Appendix D of protocol for breast cancer grading and staging information.
- •Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and HER-2 status
- •Subjects must be receiving or be scheduled to receive standard of care systemic adjuvant or neoadjuvant chemotherapy and/or endocrine therapy and/or HER-2 targeted therapy
- •For subjects receiving adjuvant therapy only:
- •- Subjects must have undergone complete resection of the primary tumor with clean surgical margins, or
- •- Subjects must have undergone resection of the primary tumor and be scheduled for further treatment of the primary tumor with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization
- •- Time between definitive surgery and randomization must be = 12 weeks
- •Definitive surgery may include secondary interventions (e.g. to clear inadequate surgical margins)
- •- Subjects with node positive disease must have undergone radical treatment of axillary LN with curative intent, or
- •Subjects must be scheduled for further treatment of regional lymph nodes with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization
- •- Subjects must not have received prior neoadjuvant treatment
- •Endocrine treatment for less than 30 days prior to surgery is not
- •considered prior neoadjuvant treatment
- •For subjects receiving neoadjuvant therapy only:
- •- Time between start of neoadjuvant treatment and randomization must be = 8 weeks
- •- Subjects must be scheduled to undergo definitive treatment (including surgery and/or radiotherapy) with curative intent within approximately 9 months of starting neoadjuvant treatment
- •Demographic
- •Female subjects with age = 18 years
- •Subjects with reproductive potential must have a negative pregnancy test within 14 days before randomization
- •Serum calcium or albumin-adjusted serum calcium = 2.0 mmol/L (8.0 mg/dL) and = 2.9 mmol/L (11.5 mg/dL)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Written informed consent before any study-specific procedure is performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3919
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 590
排除标准
- •Disease related
- •Prior or current evidence of any metastatic involvement of any distant site
- •History of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the current diagnosis
- •Medical Conditions
- •Osteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six months
- •Any prior or synchronous malignancy (other than breast cancer), except:
- •- Malignancy treated with curative intent and with no evidence of disease for = 5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician
- •- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Active infection with Hepatitis B virus or Hepatitis C virus
- •Known infection with human immunodeficiency virus (HIV)
- •Oral/ Dental Conditions
- •Prior history or current evidence of osteomyelitis/osteonecrosis of the jaw
- •Active dental or jaw condition which requires oral surgery
- •Planned invasive dental procedure for the course of the study
- •Non-healed dental or oral surgery
- •Medications/ Treatments
- •Use of oral bisphosphonates within the past 1 year
- •Prior or current IV bisphosphonate administration
- •Prior administration of denosumab
- •Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s)
- •Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
- •Subject is of child bearing potential and is not willing to use, in combination with her partner, 2 highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatment
- •Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
- •Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
- •Any major medical or psychiatric disorder that in the opinion of the investigator might prevent the subject from completing the study or interfere with the interpretation of the study results
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectioCrohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000886-19-ATMillennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)96
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer PaiEUCTR2005-001725-28-ATGlaxoSmithKline R & D Limited750
进行中（未招募）
1 期
A Phase 2b study to demonstrate the safety and efficacy of Tildrakizumab in patients with Active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000018188Psoriatic ArthritisEUCTR2016-003937-62-HUSUN Pharma Global FZE360
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-002414-39-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Anamorelin HCL in Patients with Non Small Cell Lung CancerCTRI/2011/091/000299Helsinn Therapeutics US Inc228